Align Technology Wins China Patent Ruling Against Angelalign
Align Technology has secured a patent ruling victory in China against its competitor Angelalign.
25 stories found
Align Technology has secured a patent ruling victory in China against its competitor Angelalign.
Investors are anticipating the release of Align Technology's next quarterly earnings report, with expectations for its financial performance.
Align Technology has announced a board shakeup, with Kevin Conroy set to succeed the retiring C. Raymond Larkin as Chairman.
Align Technology highlighted new Invisalign solutions, financing options, and strategies for global growth during its recent update.
Align Technology, a global medical device company, is set to establish a $200 million manufacturing facility in India. This investment signifies the company's expansion plans and commitment to the Indian market.
The transcript for Align Technology's (ALGN) first-quarter 2026 earnings call has been released, providing details on the company's financial performance and outlook.
Activist investor Elliott Management has reportedly built a significant stake in Align Technology, the maker of Invisalign, signaling potential changes or strategic pressure on the company, as reported by Bloomberg News and Reuters.
Align Technology has received an upgrade from Barclays, with the analyst firm citing valuation as the primary reason for the improved rating.
The article examines whether Wall Street analysts hold a bullish or bearish outlook on Align Technology stock, providing insights into investor sentiment.
Align Technology has outlined a target of a 100 basis point increase in its operating margin by 2027 and plans for $400-$500 million in share buybacks in 2026.
Align Technology is defending its business practices and has pledged full cooperation with an ongoing European Union probe.
An analysis questions whether Align Technology stock is currently underperforming compared to the Dow Jones Industrial Average.
Align Technology has announced record shipments of its aligner products, leading Stifel to maintain a bullish rating on the stock with a $210 target.
Bares Capital has highlighted Align Technology Inc. (ALGN) and Etsy Inc. (ETSY) as premier investment opportunities. The firm considers these companies among the best stocks to buy.
A summary of the leading Wall Street analyst research calls for Wednesday, covering various companies including Align Technology, American Tower, Autodesk, and others.
Align Technology (ALGN) is anticipating robust growth in international markets, indicating positive global expansion for the company.
An article investigates whether Align Technology's stock is currently outperforming the Nasdaq index.

Align Technology is set to add new directors to its board and initiate a review of its operations following an agreement reached with activist investor Elliott.
The European Union has initiated an antitrust probe into Align Technology, focusing on its Invisalign products and scanner tying practices. The investigation will examine potential anti-competitive behavior by the company.
Jeff Bezos's investment portfolio includes several prominent companies, with Alphabet Inc., Denali Therapeutics Inc., GRAIL, Inc., Remitly Global Inc., Nextdoor Holdings Inc., Rivian Automotive, Workday, Inc., Uber Technologies, and Airbnb, Inc. identified as some of his top stock picks. These selections highlight his investment strategy across various sectors.
Wall Street analysts have provided their target price assessments for Align Technology stock, offering insights into its potential market performance.
Align Technology has provided a Q2 revenue forecast of $1.04 billion to $1.06 billion and reiterated its projected revenue growth of 3%-4% for 2026.
Investors are anticipating the release of Align Technology's first-quarter 2026 earnings report, with analysts providing insights into what financial performance to expect.

Eli Lilly shares have slid following multiple bearish Wall Street analyst calls and downgrades, with concerns raised about the risk/reward balance and a potentially overhyped obesity drug market.
Align Technology's CFO noted market stability, with volume rising 8% and revenue up 5%, during a presentation at the Barclays Conference.